

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/269525 A1

(51) International Patent Classification:

A61K 31/416 (2006.01) *A61K 31/517* (2006.01)
A61K 31/436 (2006.01) *A61K 31/519* (2006.01)
A61K 31/4439 (2006.01) *A61K 31/5377* (2006.01)
A61K 31/4965 (2006.01) *A61K 45/06* (2006.01)
A61K 31/497 (2006.01) *A61P 35/00* (2006.01)
A61K 31/506 (2006.01) *A61P 35/04* (2006.01)

(21) International Application Number:

PCT/IB2022/055820

(22) International Filing Date:

23 June 2022 (23.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/214,001 23 June 2021 (23.06.2021) US
63/328,442 07 April 2022 (07.04.2022) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **BRACHMANN, Saskia Maria**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **COTESTA, Simona**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **CUI, Xiaoming**; Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US). **DE KANTER, Ruben**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **FARAGO, Anna**; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **GERS-PACHER, Marc**; Novartis Pharma AG, 4002 Basel (CH). **GRAUS PORTA, Diana**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **KIM, Jaeyeon**; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **LEBLANC, Catherine**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **LORTHOIS, Edwige Liliane Jeanne**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **MACHAUER, Rainer**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **MAH, Robert**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **MURA, Christophe**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **RIGOLLIER, Pascal**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **PRAHALLAD, Anirudh Cadapa**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **SCHNEIDER, Nadine**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **STRINGER, Rowan**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **STUTZ, Stefan**; Gundeldingerrein 53, 4059 Basel (CH). **VAUPEL, Andrea**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **WARIN,**

Nicolas; Novartis Pharma AG, Postfach, 4002 Basel (CH). **WILCKEN, Rainer**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **WEISS, Andreas**; Novartis Pharma AG, Postfach, 4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS

(57) Abstract: The present invention relates to a pharmaceutical combination comprising a KRAS G12C inhibitor and one or more therapeutic agents which is selected from an agent targeting the MARK pathway or an agent targeting parallel pathways; and pharmaceutical compositions comprising the same. The invention also relates to KRAS G12C inhibitors alone or said combinations for use in methods of treating a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutant.



WO 2022/269525 A1